Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia

Djamila Labib Ghafuri, Shruti Chaturvedi, Mark Rodeghier, Sarah Jo Stimpson, Brandi McClain, Jeannie Byrd, Michael R. DeBaun

Research output: Contribution to journalArticlepeer-review

Abstract

In a retrospective cohort study, we tested the hypothesis that when prescribing hydroxyurea (HU) to children with sickle cell anemia (SCA) to prevent vaso-occlusive events, there will be a secondary benefit of maintaining low transcranial Doppler (TCD) velocity, measured by imaging technique (TCDi). HU was prescribed for 90.9% (110 of 120) of children with SCA ≥5 years of age and followed for a median of 4.4 years, with 70% (n = 77) receiving at least one TCDi evaluation after starting HU. No child prescribed HU had a conditional or abnormal TCDi measurement. HU initiation for disease severity prevention decreases the prevalence of abnormal TCDi velocities.

Original languageEnglish (US)
Article numbere26401
JournalPediatric Blood and Cancer
Volume64
Issue number7
DOIs
StatePublished - Jul 2017
Externally publishedYes

Keywords

  • hydroxyurea therapy
  • red cells
  • sickle cell disease
  • transcranial Doppler velocity

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia'. Together they form a unique fingerprint.

Cite this